Navigation Links
Latest research suggests moderate coffee consumption is not associated with increased CVD risk
Date:9/27/2013

Coffee is one of the most extensively researched components in the diet. New studies are regularly being added to the already large body of scientific research, which overall suggests that moderate habitual coffee consumption is not associated with detrimental effects on cardiovascular health

Among recent studies, a new review paper1 highlights that for most healthy people, moderate coffee consumption is unlikely to adversely affect cardiovascular health. Furthermore a new paper2 concluded that higher green tea and coffee consumption is inversely associated with risk of CVD and stroke in the general population.

Considerable research has also been devoted to investigating associations between coffee consumption and key risk factors for cardiovascular disease, such as hypertension (high blood pressure) and elevated cholesterol. Most evidence suggests that regular moderate consumption of caffeinated coffee has no long-term effect on blood pressure and does not increase the risk of hypertension.

A recent study suggests that moderate consumption of paper-filtered coffee may have an unfavourable effect on plasma cholesterol3. The wider body of evidence indicates that the impact of coffee on cholesterol is dependent on the brewing method. Unfiltered coffee raises serum cholesterol levels whereas this is not the case with filter coffee because the cholesterol-raising compounds in coffee are retained in the paper filter.

Throughout 2013 coffee and mortality has been a subject of several scientific research papers, which have produced conflicting results. One study4 found a 21% increase in mortality rate in those drinking more than 28 cups of coffee a week. However recent data from a meta-analysis and systematic review5 assessed 23 studies and concluded that coffee consumption is, in fact, inversely related to the risk of mortality.


'/>"/>

Contact: Emma Knott
ISIC_Kaizo@kaizo.co.uk
020-317-64706
Kaizo
Source:Eurekalert

Page: 1

Related biology news :

1. Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
2. Latest Southern Ocean research shows continuing deep ocean change
3. Coral reef experts to present latest coral reef science during July symposium
4. American Society for Microbiologys newest journal earns a high impact factor in latest rankings
5. BGI reports the latest finding on NMNAT1 mutations linked to Leber congenital amaurosis
6. MedNet Solutions Announces Latest Enhancements To Its iMedNet EDC eClinical Solution
7. American Physiological Societys latest conference focuses on integrative biology of exercise
8. Integrative and comparative biologists to discuss latest research
9. DDW: The latest and most thought-provoking research in GI
10. The latest genomic studies of wheat sheds new light on crop adaptation and domestication
11. Conference to highlight latest in postharvest pest control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2015)... and TELTOW, Germany , August 10, ... (SMI), a world leader in Eye Tracking Technology for ... its OEM Eye Tracking Platform for integration into all ... contains reference designs for seamless integration of eye tracking ... reality HMDs and augmented reality smart glasses. Omnivision,s leading ...
(Date:8/6/2015)... TELTOW, Germany , August 6, 2015 ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted ... this new solution, unprecedented quality and efficiency is brought ... context-sensitive displays. For the first time, professionals and researchers ...
(Date:8/5/2015)... , August 5, 2015 ... titled "Facial Recognition Market - Global Industry Analysis, Size, ... global market for facial recognition is forecast to reach ... by increased demand for surveillance systems by civil and ... number of crimes and terrorist activities across the globe ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... University of California, Berkeley, scholar and Italian experts are at ... paintings or the art of ancient glassblowers. Instead, the team ... of fungi in Italy to create an unprecedented DNA database. ... - many of which are quite rare - are housed ...
... protein "transit system" may lie at the heart of ... , In the Sept. 17 online issue of Nature ... of a mutation that causes severe skeletal deformities in ... , The findings are surprising, said Ela Knapik, ...
... researchers at the University of Alberta in Edmonton, Canada have ... an ancient mammal that still defies classification. , The findings, ... and only comprehensive account of the creature, named Horolodectes sunae, ... Horolodectes lived about 60 million years ago, soon after the ...
Cached Biology News:Researchers barcode DNA of Venice museum's vast fungi collection 2Researchers barcode DNA of Venice museum's vast fungi collection 3Researchers barcode DNA of Venice museum's vast fungi collection 4Cellular traffic backups implicated in skeletal malformations 2Cellular traffic backups implicated in skeletal malformations 3Researchers give name to ancient mystery creature 2
(Date:8/26/2015)... VANCOUVER , Aug. 26, 2015 /PRNewswire/ - iCo ... ICOTF), today reported financial results for the quarter ... are expressed in Canadian dollars and presented under ... continue pre-clinical activities with respect to our Oral ... of a contract manufacturer," said Andrew Rae ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes ... the University of Miami Miller School of Medicine, ... clinical trial to test for the first time ... successfully completed.  This FDA approved Phase I/II study ... transplantation and is an important first step toward ...
(Date:8/26/2015)... BEIJING , August 26, 2015 ... DiaCardio wins 1 st place  Wayerz ... led in Israel by venture capital fund ... countries including the US, China , ... Latin America .  Impressive achievement for the Israeli ...
(Date:8/26/2015)... 26, 2015 Despite recent ... the optimism in biotech,s forecast is the recent ... sciences advancements.  Active biotechnology & healthcare companies with ... (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: SQNM ), ... Pharmaceutical Corp. (NASDAQ: RPTP ) and EnteroMedics ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
... CHICAGO, Jan. 4, 2011 Advanced Life Sciences ... ), a biopharmaceutical company engaged in the discovery, development ... of infection, oncology and respiratory diseases, today announced that ... Healthcare Conference held January 10-12th in San Francisco. ...
... LANSING, Mich., Jan. 4, 2011 Neogen Corporation (Nasdaq: ... the second quarter of FY 2011, which ended Nov. 30, ... in the quarter rose to $6,110,000, or $0.26 per share, ... revenues increased 25% to $43,931,000, compared to the prior year,s ...
... Vaccinex, Inc. announced today that it has received clearance ... trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics ... advanced solid tumors. (Logo: http://photos.prnewswire.com/prnh/20101101/NY92716LOGO ) ... blocks the activity of semaphorin 4D (SEMA4D).  It is ...
Cached Biology Technology:Advanced Life Sciences to Present at the Biotech Showcase™ 2011 Conference 2Neogen Reports 33% Increase in Net Income 2Neogen Reports 33% Increase in Net Income 3Neogen Reports 33% Increase in Net Income 4Neogen Reports 33% Increase in Net Income 5Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors 2
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
Request Info...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Biology Products: